English

• 

• 1. [1] S. Moncada, Nitric oxide: discovery and impact on clinical medicine, J. R. Soc. Med. 92 (1999) 164-169.[1] S. Moncada, Nitric oxide: discovery and impact on clinical medicine, J. R. Soc. Med. 92 (1999) 164-169.

  2. [2] P.J. Andrew, B. Mayer, Enzymatic function of nitric oxide synthases, Cardiovasc. Res. 43 (1999) 521-531.[2] P.J. Andrew, B. Mayer, Enzymatic function of nitric oxide synthases, Cardiovasc. Res. 43 (1999) 521-531.

  3. [3] J.O. Lundberg, E. Weitzberg, NO generation from nitrite and its role in vascular control, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 915-922.[3] J.O. Lundberg, E. Weitzberg, NO generation from nitrite and its role in vascular control, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 915-922.

  4. [4] R.M. Touyz, E.L. Schiffrin, Reactive oxygen species in vascular biology: implications in hypertension, Histochem. Cell Biol. 122 (2004) 339-352.[4] R.M. Touyz, E.L. Schiffrin, Reactive oxygen species in vascular biology: implications in hypertension, Histochem. Cell Biol. 122 (2004) 339-352.

  5. [5] J.E. Albina, J.S. Reichner, Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis, Cancer Metastasis Rev. 17 (1998) 39-53.[5] J.E. Albina, J.S. Reichner, Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis, Cancer Metastasis Rev. 17 (1998) 39-53.

  6. [6] F. Dodd, M. Limoges, R.T.M. Boudreau, et al., _L-Arginine inhibits apoptosis via a NO-dependent mechanism in Nb2 lymphoma cells, J. Cell. Biochem. 77 (2000) 624-634.[6] F. Dodd, M. Limoges, R.T.M. Boudreau, et al., _L-Arginine inhibits apoptosis via a NO-dependent mechanism in Nb2 lymphoma cells, J. Cell. Biochem. 77 (2000) 624-634.

  7. [7] L.A. Ridnour, K.M. Barasch, A.N. Windhausen, et al., Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation, PLoS ONE 7 (2012) e44081.[7] L.A. Ridnour, K.M. Barasch, A.N. Windhausen, et al., Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation, PLoS ONE 7 (2012) e44081.

  8. [8] V. Umansky, V. Schirrmacher, Nitric oxide-induced apoptosis in tumor cells, Adv. Cancer Res. 82 (2001) 107-131.[8] V. Umansky, V. Schirrmacher, Nitric oxide-induced apoptosis in tumor cells, Adv. Cancer Res. 82 (2001) 107-131.

  9. [9] D.D. Thomas, M.G. Espey, L.A. Ridnour, et al., Hypoxic inducible factor 1a, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8894-8899.[9] D.D. Thomas, M.G. Espey, L.A. Ridnour, et al., Hypoxic inducible factor 1a, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8894-8899.

  10. [10] L.A. Ridnour, D.D. Thomas, C. Switzer, et al., Molecular mechanisms for discrete nitric oxide levels in cancer, Nitric Oxide 19 (2008) 73-76.[10] L.A. Ridnour, D.D. Thomas, C. Switzer, et al., Molecular mechanisms for discrete nitric oxide levels in cancer, Nitric Oxide 19 (2008) 73-76.

  11. [11] S. Mocellin, V. Bronte, D. Nitti, Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities, Med. Res. Rev. 27 (2007) 317-352.[11] S. Mocellin, V. Bronte, D. Nitti, Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities, Med. Res. Rev. 27 (2007) 317-352.

  12. [12] S. Korde Choudhari, G. Sridharan, A. Gadbail, V. Poornima, Nitric oxide and oral cancer: a review, Oral Oncol. 48 (2012) 475-483.[12] S. Korde Choudhari, G. Sridharan, A. Gadbail, V. Poornima, Nitric oxide and oral cancer: a review, Oral Oncol. 48 (2012) 475-483.

  13. [13] S.Y. Ryu, S.U. Choi, S.H. Lee, et al., Antitumor triterpenes from medicinal plants, Arch. Pharm. Res. 17 (1994) 375-377.[13] S.Y. Ryu, S.U. Choi, S.H. Lee, et al., Antitumor triterpenes from medicinal plants, Arch. Pharm. Res. 17 (1994) 375-377.

  14. [14] Y. Kashiwada, F. Hashimoto, L.M. Cosentino, et al., Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents, J. Med. Chem. 39 (1996) 1016-1017.[14] Y. Kashiwada, F. Hashimoto, L.M. Cosentino, et al., Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents, J. Med. Chem. 39 (1996) 1016-1017.

  15. [15] F. Li, R. Goila-Gaur, K. Salzwedel, et al., PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13555-13560.[15] F. Li, R. Goila-Gaur, K. Salzwedel, et al., PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13555-13560.

  16. [16] E. Pisha, H. Chai, I.S. Lee, et al., Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis, Nat. Med. 1 (1995) 1046-1051.[16] E. Pisha, H. Chai, I.S. Lee, et al., Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis, Nat. Med. 1 (1995) 1046-1051.

  17. [17] L. Fang, Y.H. Zhang, J. Lehmann, et al., Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety, Bioorg. Med. Chem. Lett. 17 (2007) 1062-1066.[17] L. Fang, Y.H. Zhang, J. Lehmann, et al., Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety, Bioorg. Med. Chem. Lett. 17 (2007) 1062-1066.

•